PALM BEACH, FL, April 16, 2018 (GLOBE NEWSWIRE) — Vegalab US (“the Company”) (OTCQB: VEGL), is pleased to announce, that its CEO, David Selakovic, was interviewed for the most recent issue of the OTC Markets News Letter. The newsletter was published on April 12, 2018 and is available by clicking here.
During his interview, David Selakovic, CEO of Vegalab Inc., provided a historical overview of the Company, underscored the diversity of the Company’s product lines, highlighted the importance of the M&G Packing acquisition which had approximately $8.6 million in annual fruit sales last year, and how the he intends to increase production at M&G Packing by 200%. David also discussed the importance of the recent $13 million Master Distribution Agreement with Stanislaus Farm Supply, which is contributing to Vegalab’s increasing sales. The interview concludes with a discussion of future opportunities to better communicate with shareholders and the investing community.
About Vegalab, Inc.
Vegalab, Inc. is the exclusive distributor in North and South America of a line of all-natural, biologically derived pesticides, fertilizers, and specialty agricultural products. Vegalab’s pesticides are highly effective against targeted organisms, non-toxic to beneficial organisms, and safe for the environment. Vegalab products support a healthy soil biome and are cost competitive with synthetic chemicals that do just the opposite.
Safe Harbor for Forward-looking Statements
This news release may contain forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. While these statements are made to convey to the public the company’s progress, business opportunities, and growth prospects, they are based on management’s current beliefs and assumptions as to future events. However, since the company’s operations and business prospects are always subject to risk and uncertainties, the forward-looking events and circumstances discussed in this news release might not occur, and actual results could differ materially from those described, anticipated, or implied. For a more complete discussion of such risks and uncertainties, please refer to the company’s filings with the Securities and Exchange Commission.
636 US Highway 1, suite 110
North Palm Beach, FL 33408, US
T + 800 208 1680 ext 714